CD105/endoglin expression in Gorham disease of bone

Journal of Clinical Pathology

Volumn 62, Issue 2, 2009, Pages 163-167

  Franchi, A ^a,d   Bertoni, F ^b   Bacchini, P ^b   Mourmouras, V ^c   Miracco, C ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Department of Human Pathology and Oncology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN;

ADOLESCENT; ADULT; ARTICLE; BONE DISEASE; BONE TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GROWTH PLATE; HEMANGIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASSIVE OSTEOLYSIS; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ANTIGENS, CD; BIOLOGICAL MARKERS; BONE AND BONES; BONE NEOPLASMS; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; FEMALE; FETUS; HEMANGIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OSTEOLYSIS, ESSENTIAL; RECEPTORS, CELL SURFACE; YOUNG ADULT;

EID: 61449259921     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.060160     Document Type: Article

References (35)

1. Gorham LW, Wright AW, Shultz HH, et al. Disappearing bones: a rare form of massive osteolysis: report of two cases, one with autopsy findings. Am J Mad 1954;17:674-82.
2. Gorham LW, Stout AP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone): its relation to hemangiomatosis. J Bona Joint Surg [Am] 1955;37A:985-1004.
3. Dickson GR, Hamilton A, Hayes D, et al. An investigation of vanishing bone disease. Bona 1990;11:205-10.
4. Shives TC, Beabout JW, Unni KK. Massive osteolysis. Clin Orthop Relat Res 1993;294:267-76.
5. Moller G, Priemel M, Amling M, et al. The Gorham-Stout syndrome (Gorham's massive osteolysis): a report of six cases with histopathological findings. J Bona Joint Surg [Br] 1999;81-B:501- 6.
6. HirayamaT, Sabokbar A, Itonaga I, et al. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol 2001;195:624-30.
7. Devlin RD, Bone HG 3rd, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Matab 1996;81:1893-7.
8. Gougos A, Letarte M. Primary structure of endoglin, an RGD containing glycoprotein of human endothelial cells. J Biol Cham 1990;265:8361-4.
9. Derynck R, Feng XH. TGF-p receptor signaling. Biochim Biophys Acta 1997;1333:F105-50.
10. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1:1623-34.
11. Letarte M, Greaves A, Vera S. CD105 (endoglin). In: Schlossman SF, Baumsell L, Gilks W, eds. Laukocyta typing. Oxford: Oxford University Press, 1995:1756-9.
12. Colucci S, Taraboletti G, Primo L, et al. Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J Bona Minar Res 2006;21:207-18.
13. Botella LM, Sanchez-Elsner T, Ruis C, et al. Identification of a critical Sp1 site within the endoglin promoter and its involvement in transforming growth factor-p stimulation. J Biol Chem 2001;276:34486-94.
14. Li C, Hampson I N, Hampson L, et al. CD105 antagonizes the inhibitory signaling of transforming growth factor p1 on human vascular endothelial cells. FASEB J 2000;14:55-64.
15. Fonsatti E, Jekunen AP, Kairemo KJA, et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000;6:2037-43.
16. Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-p-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568-72.
17. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-7.
18. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-51.
19. Wang JM, Kumar S, Pye D, et al. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 1994;86:386-8.
20. Seon BK, Matsuno F, Haruta Y, et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031-44.
21. Bodey B, Bodey B Jr, Siegel SE, et al. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Anti Cancer Res 1998;18:3621-8.
22. Bodey B, Bodey B Jr, Siegel SE, et al. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anti Cancer Res 1998;18:2701-10.
23. Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-p-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568-72.
24. Tirakotai W, Fremann S, Soerensen N, et al. Biological activity of pediatric cerebral cavernomas: an immunohistochemical study of 28 patients. Childs Narv Syst 2006;22:685-91.
25. Hammer F, Kenn W, Wesselmann U, et al. Gorham-Stout disease-stabilization during bisphosphonate treatment. J Bona Minar Res 2005;20:350-3.
26. Hagendoorn J, Padera TP, Yock TI, et al. Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol 2006;3:693-7.
27. Maier JA, Delia D, Thorpe PE, et al. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 [TNP-470] and the anti-endoglin antibody TEC-11. Anti Cancer Drugs 1997;8:238-44.
28. She X, Matsuno F, Harada N, et al. Synergy between anti-endoglin [CD105] monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 2004;108:251-7.
29. Seon BK, Matsuno F, Haruta Y, et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031-44.
30. Matsuno F, Haruta Y, Kondo M, et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5:371-82.
31. Tabata M, Kondo M, Haruta Y, et al. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999;82:737-42.
32. Takahashi N, Haba A, Matsuno F, et al. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeRes by anti-endoglin [CD105] monoclonal antibodies, and synergy between antiendoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-54.
33. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Padiatrics 2007;119:e1239-47.
34. Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000;89:122-6.
35. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association ofserum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001;7:524-32.